Phosphorylated TTP Biomarker for Targeted Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for suitable biomarkers to assess whether a patient is likely to respond to a treatment with targeted therapy compounds, such as protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds, due to the high occurrence of side effects associated with various drugs.
Innovation Solution
The method involves determining the level of phosphorylated tristetraprolin (TTP) in a tumor sample and comparing it to a control. An increased level of phosphorylated TTP indicates that the patient is likely to respond to treatment with a targeted therapy compound. This method can also identify the most effective targeted therapy compound for personalized medicine by reducing the levels of phosphorylated TTP upon treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If targeted therapy compounds are administered to treat cancer, then treatment effectiveness may be improved, but side effects occur with high frequency
Solution Approach 1:
The patent applies preliminary action by measuring phosphorylated TTP levels in tumor samples before administering targeted therapy compounds. This pre-treatment biomarker assessment predicts which patients are likely to respond effectively to specific kinase inhibitors, allowing clinicians to select the most appropriate therapy in advance and avoid ineffective treatments that would expose patients to unnecessary side effects without providing therapeutic benefit.
2Adaptability or versatility
If phosphorylated TTP levels are measured to predict treatment response, then personalized treatment selection is improved, but additional testing time and complexity are required
Solution Approach 1:
The method performs the biomarker measurement as a preliminary step before treatment decisions are made. By establishing phosphorylated TTP levels in advance from tumor samples, the system enables personalized treatment selection without delaying the overall treatment timeline, as the testing can be performed on available biopsy material during the diagnostic workup phase.
3Reliability
If phosphorylated TTP levels are measured to predict treatment response, then treatment effectiveness is improved, but device complexity and testing procedures increase
Solution Approach 1:
The patent employs Western blotting and immunoprecipitation techniques to detect phosphorylated TTP levels, replacing the need for complex functional assays or multiple biomarker panels. These established molecular biology methods use commercially available antibodies and standard laboratory procedures to specifically detect the phosphorylation state of TTP, providing reliable treatment prediction through well-characterized, reproducible techniques rather than complex or proprietary systems.
Data Source
AI summary
The present invention relates to a method of determining if a patient is likely to respond to a treatment with a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds. The present invention further relates to a method of identifying a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for personalized medicine. The present invention also relates to a method of treatment of cancer in a patient. The present invention also relates to a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for use in a method of treatment of cancer in a patient.